Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2

被引:55
|
作者
Kyzas, PA [1 ]
Stefanou, D [1 ]
Batistatou, A [1 ]
Agnantis, NJ [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Pathol, GR-45110 Ioannina, Greece
关键词
VEGF; VEGFR-2; VEGFR-1; angiogenesis inhibitors;
D O I
10.1038/modpathol.3800295
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular endothelial growth factor is a peptide with well-defined actions on the vasculature and fundamental role in tumor angiogenesis. Its action in vascular endothelium is exerted in a paracrine manner. The immunohistochemical expression of this protein by cancer cells in head and neck squamous cell carcinoma was correlated with increased tumor aggressiveness and poor survival in previous studies. In the past years, an increasing amount of studies demonstrated potential autocrine action of vascular endothelial growth factor in various neoplasms. However, the existence and the impact of such autocrine action in head and neck cancer have not been demonstrated yet. In this retrospective study, we evaluated the expression of vascular endothelial growth factor and its receptors in neoplastic cells, in a cohort of patients with head and neck squamous cell carcinoma, and compared this expression with tumor aggressiveness, clinicopathologic parameters and outcome. High expression of vascular endothelial growth factor was strongly correlated with high expression of vascular endothelial growth factor receptor-2 (but not vascular endothelial growth factor receptor-1) on the cancer cells (P<0.001). The co-overexpression of both the protein and vascular endothelial growth factor receptor-2 was associated with higher tumor proliferation rate (P<0.001). The above co-overexpression also correlated with worse survival (log rank P<0.05) in patients with oral-larynx squamous cell carcinoma. Our results suggest that an autocrine vascular endothelial growth factor loop, mediated via vascular endothelial growth factor receptor-2, probably exists in head and neck squamous cell carcinoma. These observations support the hypothesis that the use of vascular endothelial growth factor receptor-2 inhibitors as adjuvant antiangiogenic therapy might have beneficial effects for these patients, by disrupting both paracrine (endothelial-dependent) and autocrine actions of vascular endothelial growth factor.
引用
收藏
页码:485 / 494
页数:10
相关论文
共 50 条
  • [41] Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition
    Holmes, Katherine
    Roberts, Owain Ll
    Thomas, Angharad M.
    Cross, Michael J.
    CELLULAR SIGNALLING, 2007, 19 (10) : 2003 - 2012
  • [42] Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
    Strizzi, L
    Catalano, A
    Vianale, G
    Orecchia, S
    Casalini, A
    Tassi, G
    Puntoni, R
    Mutti, L
    Procopio, A
    JOURNAL OF PATHOLOGY, 2001, 193 (04): : 468 - 475
  • [43] Vascular Endothelial Growth Factor and Type 2 Receptor for This Factor in Vascular Malformations
    Pavlov, K. A.
    Gershtein, E. S.
    Dubova, E. A.
    Shchegolev, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2011, 150 (04) : 481 - 484
  • [44] Vascular Endothelial Growth Factor and Type 2 Receptor for This Factor in Vascular Malformations
    K. A. Pavlov
    E. S. Gershtein
    E. A. Dubova
    A. I. Shchegolev
    Bulletin of Experimental Biology and Medicine, 2011, 150 : 481 - 484
  • [45] Vascular Endothelial Growth Factor Receptor-2 Promotes the Development of the Lymphatic Vasculature
    Dellinger, Michael T.
    Meadows, Stryder M.
    Wynne, Katherine
    Cleaver, Ondine
    Brekken, Rolf A.
    PLOS ONE, 2013, 8 (09):
  • [46] Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity
    Zecchin, Annalisa
    Pattarini, Lucia
    Gutierrez, Maria Ines
    Mano, Miguel
    Mai, Antonello
    Valente, Sergio
    Myers, Mike P.
    Pantano, Sergio
    Giacca, Mauro
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2014, 6 (02) : 116 - 127
  • [47] Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist
    Grillo, Elisabetta
    Ravelli, Cosetta
    Corsini, Michela
    Ballmer-Hofer, Kurt
    Zammataro, Luca
    Oreste, Pasqua
    Zoppetti, Giorgio
    Tobia, Chiara
    Ronca, Roberto
    Presta, Marco
    Mitola, Stefania
    ONCOTARGET, 2016, 7 (23) : 35353 - 35368
  • [48] Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis
    Chiodelli, P.
    Rezzola, S.
    Urbinati, C.
    Signori, F. Federici
    Monti, E.
    Ronca, R.
    Presta, M.
    Rusnati, M.
    ONCOGENE, 2017, 36 (47) : 6531 - 6541
  • [49] Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis
    P Chiodelli
    S Rezzola
    C Urbinati
    F Federici Signori
    E Monti
    R Ronca
    M Presta
    M Rusnati
    Oncogene, 2017, 36 : 6531 - 6541
  • [50] Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 - Potential mechanisms for exacerbation of diabetic retinopathy by hypertension
    Suzuma, I
    Hata, Y
    Clermont, A
    Pokras, F
    Rook, SL
    Suzuma, K
    Feener, EP
    Aiello, LP
    DIABETES, 2001, 50 (02) : 444 - 454